BioSpace News Archive

GlaxoSmithKline’s PARP inhibitor Zejula has been approved for wider use in some cancers.

Pharma and life sciences companies strengthen their executive and leadership teams with this week’s appointments.

MaxCyte, the global cell-based therapies and life sciences company, announces two presentations at the 5th Annual Cell & Gene Therapy Congress taking place 29-30 October in London, UK, which showcase the Company’s cell therapy technology.

CluePoints, the premier provider of Risk-Based Study Execution and Data Quality Oversight Software for clinical trials, announced major expansion as it bolsters its offering with two new larger offices to accommodate its growing family of employees and contractors.

Recce Pharmaceuticals Ltd published a white paper providing pre-clinical and experimental data on its new synthetic antibiotics and outlining the market need, its anticipated market positioning and development strategy.

The area of immunotherapy and immuno-oncology has exploded in the last few years, but researchers are focused on improving the techniques.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Partnership in iABC project will accelerate Alaxia’s development of promising antimicrobial therapy for cystic fibrosis

MaxQ AI announced that its Accipio Ix™ and Accipio Ax™ intracranial hemorrhage detection software will be available on the Nuance® AI Marketplace, the first and largest portal with one-stop access to a wide range of AI diagnostic models from within the industry’s most widely used radiology reporting platform.

Synthetic biology company, Camena Bioscience, announces a significant breakthrough in DNA synthesis accuracy with the development of an innovative technology called gSynth™.